20400 Century Blvd
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. The company stands apart through its broad pipeline, built around four proprietary platform technologies;ChAdOx, MVA, SNAP-TI and SNAP-CI. These platforms are enabling the company to develop antigen-specific immunotherapeutics that aim to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance. Leading the way with a passion for science embodies everything we do at Barinthus Biotherapeutics – even our new name. Barinthus was the name of the mythological navigator who guided the legendary King Arthur of Britain by ship to the island of Avalon to be healed after he was wounded. Like Barinthus, our company aims to be a strong and resilient guide, navigating those that rely on us toward better health. In this most important journey, our vessel is the power of science and our expertise to harness it in directing the immune system to help people overcome chronic infectious diseases, autoimmunity, and cancer. While our eyes are keenly focused on moving science forward, we also draw inspiration from the past. Aligning the name of our company with an Arthurian legend is a nod to our rich UK-based history as a dedicated steward of science and unwavering champion of patients. If the past is prologue for the future, then we proudly embrace the values and technological approach that continue to be the hallmark and fabric of our company – now more than ever as we blaze on as Barinthus Biotherapeutics.
76 articles about Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, formerly Vaccitech plc, announced its financial results for the third quarter of 2023 and provided an overview of its progress.
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced the presentation of data from two HBV clinical trials at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300.
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
Vaccitech plc today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection.
Vaccitech recently expanded from the U.K. to the U.S. CEO Bill Enright explains why.
Vaccitech plc announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress.
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
Vaccitech plc will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023.
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
Vaccitech plc (NASDAQ: VACC) (the Company, we or us) today announced the dosing of the first patient in the PCA001 clinical trial (NCT05617040).
Vaccitech plc (NASDAQ: VACC) (the Company, we or us) today announced its financial results for the first quarter of 2023 and an overview of the Company’s progress.
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat and cure chronic infectious diseases, autoimmune diseases and cancer, will present topline data from the APOLLO clinical trial at the 35th Annual International Papillomavirus Conference (IPVC).
Vaccitech plc (NASDAQ: VACC) today announced positive topline final data from the HBV002 study (NCT04778904), a Phase 1b/2a clinical trial of VTP-300 in people with chronic Hepatitis B (HBV) infection.
Vaccitech plc today announced its financial results for year end 2022 and an overview of the Company’s progress.
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
Vaccitech plc today announced topline interim data from the HPV001 study (NCT04607850), a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
Vaccitech plc today announced the appointment of Nadège Pelletier, Ph.D., as Chief Scientific Officer (CSO).
Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases
Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on Monday, November 28, 2022 at 4:30 pm ET.
Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments.
Vaccitech plc announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Gemma Brown will be presenting at the following investment conferences in November.
Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B
Vaccitech plc today announced an update to the interim analysis of safety and efficacy data from its HBV002 trial (NCT04778904).
Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300
Vaccitech plc announced that the Company will be presenting an update on its Phase 1b/2a study of VTP-300, Vaccitech’s novel immunotherapy for chronic hepatitis B, at the American Association for the Study of Liver Disease - The Liver Meeting®, in Washington, D.C., November 4 – 8, 2022.
Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the dosing of the first patients in HBV003.